公开(公告)号：WO2016168444A1

公开(公告)日：2016-10-20

申请号：PCT/US2016/027501

申请日：2016-04-14

Applicant: PURDUE RESEARCH FOUNDATION OFFICE OF TECHNOLOGY COMMERCIALIZATION ,  TURRINI, Francesco ,  PANTALEO, Antonella

Inventor： TURRINI, Francesco ,  PANTALEO, Antonella ,  LOW, Philip S.

IPC: A61K31/505 ,  A61K31/506 ,  C07D239/48 ,  C07D401/12 ,  C07D403/12

CPC classification number: A61K31/506 ,  A61K31/505

Abstract: The present disclosure generally relates to methods of treating hemolytic diseases such as sickle cell anemia using kinase inhibitors, for example, compounds that inhibit the spleen tyrosine kinse (SYK). In some embodiments a method is presented to prevent thrombosis in blood vessels of patients with a hemolytic disease comprising the step of: administrating to a patient having at least one hemolytic disease a therapeutically effective amount of at least one SYK inhibitor. In some embodiments the method includes repeatedly administering the SYK kinase inhibitor to a patient.

Abstract translation: 本公开总体上涉及使用激酶抑制剂治疗溶血性疾病如镰状细胞性贫血的方法，例如抑制脾脏酪氨酸激酶（SYK）的化合物。 在一些实施方案中，提出了一种用于预防患有溶血性疾病的患者的血管中的血栓形成的方法，包括以下步骤：向具有至少一种溶血性疾病的患者施用治疗有效量的至少一种SYK抑制剂。 在一些实施方案中，该方法包括向患者重复施用SYK激酶抑制剂。

公开(公告)号：WO2016172365A1

公开(公告)日：2016-10-27

申请号：PCT/US2016/028686

申请日：2016-04-21

Applicant: PURDUE RESEARCH FOUNDATION OFFICE OF TECHNOLOGY COMMERCIALIZATION

Inventor： RICKUS, Jenna Leigh ,  HARBIN, Sherry L. ,  KAHN, Jennifer L.

IPC: C12N11/04 ,  C12N11/14

CPC classification number: C07K14/78 ,  C12N5/0012 ,  C12N5/0697 ,  C12N11/04 ,  C12N11/14

Abstract: Soluble, self-assembling collagens derived from tissues are extensively characterized such that one can predict and customize the final collagen-fibril matrix with respect to fibril microstructure (i.e.,fibril density, interfibril branching), viscoelasticity, and proteolytic degradability. As shown herein these matrices template and direct the deposition of mesoporous silica at the level of individual collagen fibrils. The fibril density, silicic acid concentration, and time of exposure to silicifying solution were varied and the resulting hybrid materials were analyzed by scanning electron microscopy, energy-dispersive x-ray spectroscopy, and rheology. Microstructural properties of the collagen-fibril template are preserved in the silica surface of hybrid materials. Results for three different collagen fibril densities, corresponding to shear storage moduli of 200 Pa, 1000 Pa, and 1600 Pa, indicate that increased fibril density increases the absolute amount of templated silica when all other silica synthesis conditions are kept constant. The mechanical properties of the hybrid material are dominated by the presence of the silica coating rather than the starting collagen matrix stiffness.

Abstract translation: 衍生自组织的可溶性自组装胶原蛋白被广泛地表征，使得人们可以相对于原纤维微结构（即原纤维密度，纤丝分支），粘弹性和蛋白水解降解性来预测和定制最终的胶原纤维基质。 如本文所示，这些基质模拟并引导介孔二氧化硅在单个胶原原纤维水平的沉积。 改变原纤维密度，硅酸浓度和暴露于硅化溶液的时间，通过扫描电子显微镜，能量色散X射线光谱和流变学分析所得的杂化材料。 胶原纤维模板的微观结构性质保留在混合材料的二氧化硅表面。 对应于200 Pa，1000 Pa和1600 Pa的剪切储存模量的三种不同胶原纤维密度的结果表明，当所有其他二氧化硅合成条件保持恒定时，增加的原纤维密度增加模板二氧化硅的绝对量。 杂化材料的机械性能由二氧化硅涂层的存在主导，而不是起始胶原基质刚度。

公开(公告)号：WO2016033322A1

公开(公告)日：2016-03-03

申请号：PCT/US2015/047176

申请日：2015-08-27

Applicant: PURDUE RESEARCH FOUNDATION OFFICE OF TECHNOLOGY COMMERCIALIZATION

Inventor： VOYTIK-HARBIN, Sherry

IPC: A61L31/04

CPC classification number: A61L27/24 ,  A61K9/0024 ,  A61K9/19 ,  A61K38/18 ,  A61K47/42 ,  A61L27/54 ,  A61L2300/414 ,  A61L2300/604 ,  A61L2400/06

Abstract: A collagen-based therapeutic delivery device includes an insoluble synthetic collagen-fibril matrix comprising a polymerization product of soluble oligomeric collagen or a polymerization product of a mixture of soluble oligomeric collagen with one or more type of non-oligomeric soluble collagen molecules, such as, for example, soluble telocollagen and/or soluble atelocollagen, and an active agent dispersed throughout the collagen-fibril matrix or within a portion of the collagen-fibril matrix. A pre-matrix composition includes an aqueous solution including soluble collagen-fibril building blocks and an active agent in the aqueous solution. The soluble collagen-fibril building blocks include soluble oligomeric collagen or a mixture of soluble oligomeric collagen with non-oligomeric soluble collagen molecules. The building blocks are operable to self-assemble into a macromolecular synthetic collagen-fibril matrix in the absence of an exogenous cross-linking agent. Methods of making and using the pre-matrix composition and the device are also provided.

Abstract translation: 基于胶原的治疗递送装置包括不溶性合成胶原纤维基质，其包含可溶性低聚胶原的聚合产物或可溶性低聚胶原与一种或多种类型的非低聚可溶性胶原分子的混合物的聚合产物， 例如可溶性胶原蛋白和/或可溶性胶原蛋白，以及分散在整个胶原 - 原纤维基质或胶原 - 原纤维基质的一部分内的活性剂。 前体基质组合物包括在水溶液中包含可溶性胶原 - 原纤维结构单元和活性剂的水溶液。 可溶性胶原纤维结构单元包括可溶性低聚胶原蛋白或可溶性低聚胶原蛋白与非低聚可溶性胶原分子的混合物。 在不存在外源交联剂的情况下，构建块可操作以自组装成大分子合成胶原原纤维基质。 还提供了制备和使用前基质组合物和装置的方法。

公开(公告)号：US10314940B2

公开(公告)日：2019-06-11

申请号：US15505046

申请日：2015-08-27

Applicant: Purdue Research Foundation Office of Technology Commercialization

Inventor： Sherry Voytik-Harbin

IPC: A61K47/42 ,  A61K9/00 ,  A61L27/24 ,  A61L27/54 ,  A61K9/19 ,  A61K38/18

Abstract: A collagen-based therapeutic delivery device includes an insoluble synthetic collagen-fibril matrix comprising a polymerization product of soluble oligomeric collagen or a polymerization product of a mixture of soluble oligomeric collagen with one or more type of non-oligomeric soluble collagen molecules, such as, for example, soluble telocollagen and/or soluble atelocollagen, and an active agent dispersed throughout the collagen-fibril matrix or within a portion of the collagen-fibril matrix. A pre-matrix composition includes an aqueous solution including soluble collagen-fibril building blocks and an active agent in the aqueous solution. The soluble collagen-fibril building blocks include soluble oligomeric collagen or a mixture of soluble oligomeric collagen with non-oligomeric soluble collagen molecules. The building blocks are operable to self-assemble into a macromolecular synthetic collagen-fibril matrix in the absence of an exogenous cross-linking agent. Methods of making and using the pre-matrix composition and the device are also provided.

公开(公告)号：US10279044B2

公开(公告)日：2019-05-07

申请号：US15578226

申请日：2016-05-29

Applicant: Purdue Research Foundation Office of Technology Commercialization ,  University of Utah Research Foundation ,  Jindrich Kopecek ,  Jiyan Yang

Inventor： Stewart Andrew Low ,  Philip S. Low ,  Christopher Galliford ,  Jindrich Kopecek ,  Jiyan Yang

IPC: A61K31/404 ,  C07D403/04 ,  C07D209/34 ,  C07D487/00 ,  A61K47/42 ,  A61L27/22 ,  A61L27/54 ,  C07K7/06 ,  C07K7/08 ,  A61P19/00 ,  A61K9/107 ,  A61M5/00

Abstract: Aspects of the present disclosure generally relate to compounds for targeting and healing bone fractures. Some of these compounds include a negatively charged oligopeptide comprising an acidic oligopeptide, a linker, which may be hydrolyzable or may be a substrate for the protease cathepsin K, and at least one molecule that promotes bone healing. In some compounds the molecule that promotes bone healing is an anabolic compound that inhibits GSK3β, in some compounds the molecule that promotes the healing of bone fracture is a pro-inflammatory agent such as PGE1. Other embodiments include methods of treating a bone fracture comprising administering a therapeutic amount of any one of the compounds disclosed herein.

公开(公告)号：US20170274120A1

公开(公告)日：2017-09-28

申请号：US15505046

申请日：2015-08-27

Applicant: Purdue Research Foundation Office of Technology Commercialization

Inventor： Sherry Voytik-Harbin

IPC: A61L27/24 ,  A61L27/54 ,  A61K38/18 ,  A61K47/42 ,  A61K9/00 ,  A61K9/19

CPC classification number: A61L27/24 ,  A61K9/0024 ,  A61K9/19 ,  A61K38/18 ,  A61K47/42 ,  A61L27/54 ,  A61L2300/414 ,  A61L2300/604 ,  A61L2400/06

Abstract: A collagen-based therapeutic delivery device includes an insoluble synthetic collagen-fibril matrix comprising a polymerization product of soluble oligomeric collagen or a polymerization product of a mixture of soluble oligomeric collagen with one or more type of non-oligomeric soluble collagen molecules, such as, for example, soluble telocollagen and/or soluble atelocollagen, and an active agent dispersed throughout the collagen-fibril matrix or within a portion of the collagen-fibril matrix. A pre-matrix composition includes an aqueous solution including soluble collagen-fibril building blocks and an active agent in the aqueous solution. The soluble collagen-fibril building blocks include soluble oligomeric collagen or a mixture of soluble oligomeric collagen with non-oligomeric soluble collagen molecules. The building blocks are operable to self-assemble into a macromolecular synthetic collagen-fibril matrix in the absence of an exogenous cross-linking agent. Methods of making and using the pre-matrix composition and the device are also provided.

公开(公告)号：US20220021239A1

公开(公告)日：2022-01-20

申请号：US17375105

申请日：2021-07-14

Applicant: Alliance for Sustainable Energy, LLC ,  Purdue Research Foundation - Office of Technology Commercialization

Inventor： Zhiwen MA ,  Jeffrey Clayton GIFFORD ,  Patrick Gordon DAVENPORT ,  Dening JIA ,  Jason SCHIRCK ,  Aaron MORRIS

IPC: H02J15/00 ,  F28D20/00

Abstract: The disclosure relates to particle heaters for heating solid particles to store electrical energy as thermal energy. Thermal energy storage directly converts off-peak electricity into heat for thermal energy storage, which may be converted back to electricity, for example during peak-hour power generation. The particle heater is an integral part of an electro-thermal energy storage system, as it enables the conversion of electrical energy into thermal energy. As described herein, particle heater designs are described that provide efficient heating of solid particles in an efficient and compact configuration to achieve high energy density and low cost.

公开(公告)号：US20180141996A1

公开(公告)日：2018-05-24

申请号：US15568262

申请日：2016-04-21

Applicant: Purdue Research Foundation Office of Technology Commercialization

Inventor： Jenna Leigh Rickus ,  Sherry L. Harbin ,  Jennifer L. Kahn

IPC: C07K14/78 ,  C12N5/071 ,  C12N5/00 ,  C12N11/14

CPC classification number: C07K14/78 ,  C12N5/0012 ,  C12N5/0697 ,  C12N11/04 ,  C12N11/14

Abstract: Soluble, self-assembling collagens derived from tissues are extensively characterized such that one can predict and customize the final collagen-fibril matrix with respect to fibril microstructure (i.e., fibril density, interfibril branching), viscoelasticity and proteolytic degradability. As shown herein these matrices template and direct the deposition of mesoporous silica at the level of individual collagen fibrils. The fibril density, silicic acid concentration, and time of exposure to silicifying solution were varied and the resulting hybrid materials were analyzed by scanning electron microscopy, energy-dispersive x-ray spectroscopy, and rheology. Microstructural properties of the collagen-fibril template are preserved in the silica surface of hybrid materials. Results for three different collagen fibril densities, corresponding to shear storage moduli of 200 Pa, 1000 Pa, and 1600 Pa, indicate that increased fibril density increases the absolute amount of templated silica when all other silica synthesis conditions are kept constant. The mechanical properties of the hybrid material are dominated by the presence of the silica coating rather than the starting collagen matrix stiffness.

公开(公告)号：US11631992B2

公开(公告)日：2023-04-18

申请号：US17375105

申请日：2021-07-14

Applicant: Alliance for Sustainable Energy, LLC ,  Purdue Research Foundation—Office of Technology Commercialization

Inventor： Zhiwen Ma ,  Jeffrey Clayton Gifford ,  Patrick Gordon Davenport ,  Dening Jia ,  Jason Schirck ,  Aaron Morris

IPC: H02J15/00 ,  F28D20/00

Abstract: The disclosure relates to particle heaters for heating solid particles to store electrical energy as thermal energy. Thermal energy storage directly converts off-peak electricity into heat for thermal energy storage, which may be converted back to electricity, for example during peak-hour power generation. The particle heater is an integral part of an electro-thermal energy storage system, as it enables the conversion of electrical energy into thermal energy. As described herein, particle heater designs are described that provide efficient heating of solid particles in an efficient and compact configuration to achieve high energy density and low cost.

公开(公告)号：US20180078552A1

公开(公告)日：2018-03-22

申请号：US15566590

申请日：2016-04-14

Applicant: Francesco Turrini ,  Antonella Pantaleo ,  Purdue Research Foundation Office of Technology Commercialization

Inventor： Phillip S. Low ,  Francesco Turrini ,  Antonella Pantaleo

IPC: A61K31/506

CPC classification number: A61K31/506 ,  A61K31/505

Abstract: The present disclosure generally relates to methods of treating hemolytic diseases such as sickle cell anemia using kinase inhibitors, for example, compounds that inhibit the spleen tyrosine kinase (SYK). In some embodiments a method is presented to prevent thrombosis in blood vessels of patients with a hemolytic disease comprising the step of: administrating to a patient having at least one hemolytic disease a therapeutically effective amount of at least one SYK inhibitor. In some embodiments the method includes repeatedly administering the SYK kinase inhibitor to a patient.